beyond pink team
  • Home
  • About Us
    • Who We Are
    • Our Board
    • Annual Report
    • Contact Us
  • Support
    • Physical
    • Emotional
    • Community
    • Financial
    • Caregiver
    • Online
  • Education
    • Newsletter
    • Ignite the Cancer Conversation
    • Quality Care
    • Resources
    • Request Speaker
    • The Cancer Journey
  • Advocacy
    • What is Advocacy
    • National Breast Cancer Coalition
    • Iowa Stop Breast Cancer
    • Research
    • Influencing Policy
    • Access to Care
  • Join Us
    • Be an Advocate
    • Volunteer
    • Events >
      • 16th Annual Pink Ribbon Run
    • Membership
    • Donate to BPT
    • Follow Us
 If you are Breast Cancer Survivor and  you would like to contribute your story to our Newsletter, 
​please send us a message here.
DOWNLOAD Current NewsletteR

Categories

All
Advocacy
Bone Health
Breast Density
Breast Disease
Caregivers
COVID 19
COVID-19
Emotional Support
Environment
Exercise
Fatigue
Financial
Gender
Genetic Testing
Grief
High Risk
Hormone Replacement Therapy
Ignite
Implants
Intimacy After Cancer
LGBTQ
Lymphedema
Mammography
Meditation
Men
Mental Health
Metastasis
MRI
NBCC
Nutrition
Obesity
Pain
Pregnancy
Prevention
Radiation
Reconstruction
Reduce Risk
Rehabilitation
Screening
Sex
Side Effects
Support Groups
Surgery
Survivor
Survivorship
Treatment
Vaccine
Yoga
Young Women

Archives

January 2023
October 2022
July 2022
April 2022
January 2022
October 2021
July 2021
April 2021
January 2021
October 2020
July 2020
April 2020
January 2020
October 2019
July 2019
April 2019
January 2019
October 2018
July 2018
April 2018
January 2018
October 2017
July 2017
April 2017
January 2017
October 2016
July 2016
April 2016
January 2016
October 2015
July 2015
April 2015
January 2015
October 2014
July 2014
April 2014
January 2014
October 2013
July 2013
April 2013
January 2013
October 2012
July 2012
April 2012
January 2012
October 2011
July 2011
April 2011
January 2011
October 2010
July 2010
April 2010
January 2010
October 2009
July 2009
April 2009
January 2009
October 2008
July 2008
April 2008
January 2008
October 2007
July 2007
April 2007
January 2007
October 2006
July 2006
April 2006
January 2006
October 2005
July 2005
April 2005
January 2005
October 2004
July 2004
April 2004
January 2004

beyond brca testing

10/1/2019

0 Comments

 
by Jeanne Olson, RN

​Genetic testing has expanded greatly in the past few years. BRCA1 & BRCA2 were the only genes tested for breast cancer in the past. Genetic testing panels are now standard. Only one out of ten (10%) women diagnosed with breast cancer have a genetic predisposition measurable by genetic testing.

Genes related to breast cancer development now include ATM, CDH1, CHEK2, PALB2, PTEN, STK11, TP53, NBN, NF1, in addition to BRCA1 & BRCA2. All of these genes have a different penetrance level, there are varying percentages of risk.

Cancer genetic panel testing also include the genes for cancers affecting colon/gastric, pancreatic, prostate, melanoma, ovarian/uterine and others. Most genes affect more than one body system.

The American Society of Breast Surgeons (ASBS) published a consensus statement this spring, stating all women with a diagnosis of breast cancer, regardless of age should be genetically tested. For those women who were tested previously only for BRCA1 & 2, they should be offered updated panel testing. It is felt that of the 10% noted above, only half of those were being identified due to the restrictive insurance company policies.
​
Genetic testing is offered locally at the cancer treatment centers, as well as the breast centers, and some primary care offices. Samples of either blood or saliva can be submitted for DNA sampling.

If you were tested for BRCA1 & BRCA2 only in the past, check with your physician about having expanded panel testing.
Genetic testing results fall into three categories: A positive/pathogenic variant, a negative result and then variants of uncertain significance (VUS).
• For those with a positive/pathogenic variant, genetic counseling is recommended. Genetic counseling can be obtained by an in-person visit – typically in Cedar Rapids, Iowa City or Mayo Clinic.
The Genetic testing companies may also offer genetic counseling via phone with a certified genetic counselor.

• A negative result is reassuring, but it doesn’t mean the patient is “off the hook” for developing any of the cancers affiliated with the genes tested, but it does mean the patient does not have a genetic predisposition to that cancer development.

• VUS – variant of uncertain significance is essentially a negative report. These variants are not actionable. VUS are followed by the genetic testing companies and over time, some of these will be upgraded to a positive/pathogenic variant, others may be downgraded to negative. When there are changes to a VUS, the ordering physician is notified. That provider’s office will notify the patient of the change. Inheriting a positive/pathogetic variant, for many of the common cancer genes, is a 50/50 chance.

If a patient is negative, her children are negative. If a patient is positive, her children would have a 50% chance of also having the same gene mutation. Costs have decreased dramatically as well. $4,000 was a commonly billed amount in the past.

Some companies will provide testing for $250 or possibly less. There is significant market share competition with the various testing companies, each have their own offers. Health insurance providers are prohibited by law from discriminating against patients with a pathologic genetic variant. This same protection is not available for life, disability and long-term care insurance.

When a patient is seeking genetic testing and has not had a cancer diagnosis, it is recommended they have these insurance policies in place before testing. Not disclosing genetic testing results on applications is fraud, a criminal offense. There are reports of Medicare fraud, where patients are contacted unsolicited, usually by phone, telling them because they have had breast cancer, they can be tested from home.

These fraudulent callers already have the patient’s Medicare number and other demographic information. If the patient agrees, a kit is sent to them, once returned, some do get a report. But there are instances of Medicare paying for the testing, but the patient never receiving a report.

​The Office of Inspector General (OIG) has open cases regarding this fraudulent activity, including locally. The recommendation is to always have your testing with a medical provider. Do not accept phone calls offering testing. The genetic/ancestry testing that is commercially available is also not recommended as those labs are not accredited with Clinical Laboratory Improvement Amendments (CLIA).
To read the complete consensus statement of the American Society of Breast Surgeons (ASBS) issued this spring can be found at https://www.breastsurgeons.org /docs/statements/ConsensusGuideline-on-Genetic-Testingfor-Hereditary-BreastCancer.pdf
​
Read Full Newsletter
0 Comments



Leave a Reply.

CONTACT US

Beyond Pink TEAM
c/o Jeanne Olson, Treasurer
1407 Asbury Lane
Waterloo, IA 50701
​beyondpinkteam@gmail.com
(319) 239-3706
©2020 Beyond Pink TEAM
  • Home
  • About Us
    • Who We Are
    • Our Board
    • Annual Report
    • Contact Us
  • Support
    • Physical
    • Emotional
    • Community
    • Financial
    • Caregiver
    • Online
  • Education
    • Newsletter
    • Ignite the Cancer Conversation
    • Quality Care
    • Resources
    • Request Speaker
    • The Cancer Journey
  • Advocacy
    • What is Advocacy
    • National Breast Cancer Coalition
    • Iowa Stop Breast Cancer
    • Research
    • Influencing Policy
    • Access to Care
  • Join Us
    • Be an Advocate
    • Volunteer
    • Events >
      • 16th Annual Pink Ribbon Run
    • Membership
    • Donate to BPT
    • Follow Us